United Therapeutics CFO sells 10K shares after exercise
United Therapeutics Corp CFO and Treasurer James Edgemond reported an options exercise and related share sales in company common stock.
Rhea-AI Filing Summary
United Therapeutics Corp CFO and Treasurer James Edgemond reported an options exercise and related share sales in company common stock. On June 8, 2026, he exercised 10,000 stock options at an exercise price of $117.76 per share to acquire 10,000 shares.
That same day, he sold 10,000 common shares in a series of open‑market transactions at weighted average prices ranging from the mid‑$540s to low‑$550s per share. According to the filing, these trades were made under a pre‑arranged Rule 10b5‑1 trading plan entered into on October 31, 2025.
Following these transactions, Edgemond directly holds 18,876 shares of United Therapeutics common stock, and the filing shows no remaining derivative (stock option) position tied to this grant.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 10,000 shares ($4.30M approx. pre-tax spread)
Exercise and Sale
10 txns
Insider
EDGEMOND JAMES
Role
CFO AND TREASURER
Sold
10,000 shs ($5.48M)
Approx. gross sale proceeds
$5.48M
Approx. exercise cost
$1.18M
Approx. pre-tax spread
$4.30M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option | 10,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 10,000 | $117.76 | $1.18M |
| Sale | Common Stock | 1,565 | $544.9334 | $853K |
| Sale | Common Stock | 1,989 | $546.1339 | $1.09M |
| Sale | Common Stock | 1,888 | $547.0292 | $1.03M |
| Sale | Common Stock | 2,158 | $547.9111 | $1.18M |
| Sale | Common Stock | 425 | $549.3819 | $233K |
| Sale | Common Stock | 1,285 | $550.0937 | $707K |
| Sale | Common Stock | 610 | $551.2826 | $336K |
| Sale | Common Stock | 80 | $551.755 | $44K |
Holdings After Transaction:
Stock Option — 20,000 contracts (Direct);
Common Stock — 18,876 shares (Direct)
Footnotes (9)
- F1. This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025.
- F2. This transaction was executed in multiple trades at prices ranging from $544.41 to $545.40. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3. This transaction was executed in multiple trades at prices ranging from $545.47 to $546.46. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4. This transaction was executed in multiple trades at prices ranging from $546.51 to $547.50. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5. This transaction was executed in multiple trades at prices ranging from $547.52 to $548.485. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F6. This transaction was executed in multiple trades at prices ranging from $548.59 to $549.56. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F7. This transaction was executed in multiple trades at prices ranging from $549.59 to $550.58. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F8. This transaction was executed in multiple trades at prices ranging from $550.63 to $551.60. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F9. This transaction was executed in multiple trades at prices ranging from $551.74 to $551.77. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Key Figures
Common shares sold: 10,000 shares
Sale price range: $544.41–$551.77 per share
Options exercised: 10,000 options
+3 more
6 metrics
Common shares sold
10,000 shares
Open-market sales of United Therapeutics common stock on June 8, 2026
Sale price range
$544.41–$551.77 per share
Weighted average prices across multiple trades on June 8, 2026
Options exercised
10,000 options
Stock options converted into common shares on June 8, 2026
Option exercise price
$117.76 per share
Exercise price for 10,000 stock options
Shares held after transactions
18,876 shares
Direct common stock ownership after June 8, 2026 trades
Option expiration date
March 15, 2027
Original expiration date of the exercised stock options
Key Terms
Rule 10b5-1 trading plan, stock options, weighted average price, derivative security, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
stock options financial
"This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
weighted average price financial
"The price reported above reflects the weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
derivative security financial
"Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
open market or private transaction financial
"Sale in open market or private transaction"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did United Therapeutics (UTHR) report for CFO James Edgemond?
United Therapeutics reported that CFO James Edgemond exercised 10,000 stock options and sold 10,000 common shares on June 8, 2026. The sales were executed in multiple open‑market trades at weighted average prices in the mid‑$540s to low‑$550s per share.
What was the exercise price of the United Therapeutics (UTHR) stock options used by the CFO?
The Form 4 shows that 10,000 stock options were exercised at an exercise price of $117.76 per share. These options, granted earlier, were converted into 10,000 shares of United Therapeutics common stock before the same‑day open‑market sales.
What happened to the CFO’s United Therapeutics stock options in this Form 4 filing?
The filing shows 10,000 stock options were exercised into 10,000 common shares on June 8, 2026, at a $117.76 exercise price. The derivative summary is empty afterward, indicating this specific option position was fully exercised with no remaining derivative shares from that grant.
AI-generated analysis. How Rhea-AI works. Not financial advice.
